David Fontana, PhD

David Fontana, PhD, is a seasoned biotech executive with over 20 years of experience driving drug development, operational excellence, and strategic growth. As CBO and COO of Umoja Biopharma, he has led corporate strategy, business development, and portfolio advancements, including securing the first FDA-cleared IND for in vivo CAR-T therapy. Previously, he played a pivotal role in launching Breyanzi at Bristol Myers Squibb and advancing Avelumab at Pfizer. With a proven track record in scaling organizations from startups to global enterprises, David is now focused on leveraging his leadership and innovation expertise to bring in vivo CAR T therapies to patients